Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of IL-1β inhibition on safety, measures
of systemic and vascular inflammation and endothelial function (all indicators of
cardiovascular risk) in treated and suppressed HIV infected individuals This study will
assess the safety and effects of canakinumab on endothelial function (assessed by
flow-mediated vasodilation [FMD] of the brachial artery), vascular inflammation (assessed by
FDG-PET/CT scanning), key inflammatory markers of cardiovascular disease (CVD) risk
(high-sensitivity C-reactive protein [hsCRP]), interleukin-6 (IL-6), soluble CD163 (sCD163),
D-dimer, T-cell and monocyte activation in the blood, and size of the HIV reservoir. 20
individuals will receive a single dose of 150mg canakinumab with follow-up for 18 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Priscilla Hsue, MD University of California, San Francisco